The differentiation of activated CD4 + T cells into the T helper type 1 (T H 1) or T H 2 fate is regulated by cytokines and the transcription factors T-bet and GATA-3. Whereas interleukin 12 (IL-12) produced by antigen-presenting cells initiates the T H 1 fate, signals that initiate the T H 2 fate are not completely characterized. Here we show that early GATA-3 expression, required for T H 2 differentiation, was induced by T cell factor 1 (TCF-1) and its cofactor b-catenin, mainly from the proximal Gata3 promoter upstream of exon 1b. This activity was induced after T cell antigen receptor (TCR) stimulation and was independent of IL-4 receptor signaling through the transcription factor STAT6. Furthermore, TCF-1 blocked T H 1 fate by negatively regulating interferon-c (IFN-c) expression independently of b-catenin. Thus, TCF-1 initiates T H 2 differentiation of activated CD4 + T cells by promoting GATA-3 expression and suppressing IFN-c expression.
After being activated, naive CD4 + T cells differentiate into helper T cell subsets to orchestrate effective immunity to microorganisms. T helper type 1 (T H 1) cells mediate immunity against intracellular viruses and bacteria, whereas T H 2 cells protect against parasites and mediate allergic responses 1, 2 . The best-characterized feature of helper T cells is that T H 1 cells produce interferon-g (IFN-g), whereas T H 2 cells produce interleukin 4 (IL-4; A001262), IL-5 and IL- 13 (refs. 3,4) . Whereas activated CD4 + T cells differentiate into the T H 1 lineage in response to IL-12 provided by antigen-presenting cells (APCs) and IFN-g produced by natural killer cells 2 , similar signals that initiate T H 2 differentiation remain incompletely characterized.
Once the T H 2 response is initiated, IL-4 production by activated CD4 + T cells reinforces the T H 2 fate 5 . However, the source of IL-4 at early stages of T H 2 differentiation remains controversial. Cells of the innate immune system that produce IL-4 and help initiate T H 2 differentiation 3 have been found to be dispensable in some circumstances 4, 6, 7 , which suggests that IL-4 produced by antigen-activated CD4 + T cells is sufficient to initiate the T H 2 response 8 . Thus, CD4 + T cells themselves have the potential to provide the initial IL-4 for T H 2 differentiation. IL-4 expression is regulated by the transcription factor GATA-3 (refs. [9] [10] [11] [12] , which is expressed from two transcripts, called 'Gata3-1a' and 'Gata3-1b' here, that initiate from regulatory regions upstream of noncoding exons 1a and 1b, respectively 13 . Various combinations of transcription factors 'downstream' of the T cell antigen receptor (TCR) and the IL-4 receptor (IL-4R; A001263) seem to regulate GATA-3 expression during T H 2 differentiation 14 . Notch-dependent signals have been shown to directly regulate GATA-3 expression and critically control helper T cell fate in vivo [15] [16] [17] [18] [19] . However, another report has suggested that Notch signals provide survival and proliferative advantages to committed helper T cells rather than direct commitment to the helper T cell fate 20 . Thus, other factors may induce GATA-3 expression, early after CD4 + T cell activation, in the absence of IL-4 in a transcription factor STAT6-independent way, but these remain to be fully described.
The transcription factor T cell factor 1 (TCF-1; A002260) represses gene expression in conjunction with Groucho 21 , and activates gene transcription by acting together with b-catenin (A000506) 'downstream' of several signaling pathways, including the canonical Wnt signaling pathway [22] [23] [24] . Several reports have demonstrated an essential function for TCF-1 and b-catenin at stages of T cell development that are regulated by the TCR or pre-TCR 25, 26 . TCF-1 has high expression in thymocytes 27 and in resting and activated human T cells 28 and mouse T cells (data presented here), and b-catenin is stabilized 'downstream' of TCR signaling in activated T cells [29] [30] [31] [32] . In addition, TCF reporter activity has been noted in activated T cells in vivo 33 . These data suggest that TCF-1 and b-catenin might participate in gene transcription in activated T cells without the requirement for Wntdependent activity. However, involvement of TCF-1 and b-catenin in the activation and differentiation of mature T cells has not been established before.
Here we demonstrate that TCF-1 and b-catenin regulated the differentiation of TCR-activated CD4 + T cells into the T H 2 lineage. Initial GATA-3 expression in activated CD4 + T cells arose mainly from Gata3-1b transcripts. Gata3-1b transcription was induced 'downstream' of TCR signals, at early time points, and was independent of IL-4R signaling through STAT6. TCF-1 and b-catenin bound to the TCF-1-recognition site upstream of Gata3 exon 1b to positively regulate GATA-3 expression. Deletion of TCF-1 resulted in less Gata3-1b expression and IL-4 production. In contrast, enforced expression of stabilized b-catenin in activated CD4 + T cells resulted in 'preferentially' higher Gata3-1b expression and IL-4 production. Moreover, enforced expression of ICAT, a specific inhibitor of the interaction of TCF-1 and b-catenin, impaired Gata3-1b expression and IL-4 production, demonstrating a functional requirement for both TCF-1 and b-catenin. TCF-1 negatively regulated IFN-g production and impaired the T H 1 fate in TCR-activated CD4 + T cells. Thus, our data demonstrate that TCF-1 and b-catenin are responsible for driving TCR-activated T cells to a T H 2 fate and do so by initiating GATA-3 expression and inhibiting IFN-g production.
RESULTS
TCR induces GATA-3 from the Gata3-1b promoter Gata3 is transcribed from two alternative promoters located 10 kilobases apart upstream of noncoding exon 1a and exon 1b 13 (Fig. 1a) . The resultant mRNA transcripts encode the same protein product but can be distinguished by the presence of promoter-specific sequences unique to exon 1a (Gata3-1a) or exon 1b (Gata3-1b). To assess GATA-3 expression, we activated CD4 + T cells with antibody to CD3 (anti-CD3) and anti-CD28 and studied the kinetics of expression of these two Gata3 transcripts. Unexpectedly, we found that Gata3-1b transcripts were 100-fold more abundant than Gata3-1a transcripts when normalized to a control gene (Fig. 1a) . This difference was not due to different primer efficiencies, as verified by PCR amplification of Gata3-1a and Gata3-1b regions from three independent preparations of genomic DNA (Fig. 1a, right) . Whereas the relative abundance of Gata3-1a transcripts remained low for the first 3 d and increased thereafter, the relative abundance of Gata3-1b transcripts increased within 24 h of CD4 + T cell activation (Fig. 1a) . At all time points after TCR stimulation of CD4 + T cells, the relative abundance of Gata3-1b transcripts was much higher than that of Gata3-1a transcripts. Thus, Gata3-1b transcripts are the main contributors to GATA-3 expression in TCR-activated CD4 + T cells.
To initiate T H 2 differentiation, Gata3 must be induced in the absence of IL-4 signaling in a STAT6-independent way. To determine if Gata3-1b transcripts were sensitive to IL-4R signaling through STAT6, we activated control and STAT6-deficient CD4 + T cells 34 with anti-CD3 and anti-CD28 in the absence of additional helper T cell-promoting agents. We found that the induction of Gata3-1b transcription in STAT6-deficient CD4 + T cells was similar to that in control CD4 + T cells (Fig. 1b) , which suggested that transcription of Gata3-1b was STAT6 independent. In addition, antibody-mediated blockade of IL-4 did not diminish the abundance of Gata3-1b transcripts (Fig. 1c) . Together these data demonstrate that early after activation of CD4 + T cells, GATA-3 is produced from Gata3-1b transcripts in a STAT6-and IL-4-independent way.
TCF-1 and b-catenin regulate Gata3-1b expression To study the transcriptional regulation of Gata3, we screened DNA sequences in the regulatory region upstream of Gata3 exon 1b. We found two closely placed binding sites for the transcription factor TCF-1 in the putative promoter region, upstream of Gata3 exon 1b. To determine if these sites functionally regulate expression of Gata3-1b, we quantified Gata3-1b mRNA in activated control and TCF-1-deficient CD4 + T cells. We purified CD25 À CD4 + T cell populations that were enriched for naive cells from both TCF-1-deficient mice 27 and control mice and confirmed that they contained similar proportions of CD62L hi CD44 lo naive cells, which were also CD25 À CD69 À . TCF-1-deficient CD4 + T cells showed normal activation in response to APCs plus anti-CD3, as indicated by upregulation of CD25 and CD69 ( Supplementary Fig. 1a ). In addition, activated TCF-1-deficient CD4 + T cells proliferated and produced IL-2 similar to control CD4 + T cells ( Supplementary Fig. 1b,c) . Notably, we found that Gata3-1b expression was lower in activated TCF-1-deficient CD4 + T cells than in wild-type CD4 + T cells (Fig. 2a) , which suggested that induction of Gata3-1b expression in CD4 + T cells after TCR stimulation required TCF-1.
As TCF-1 is not known to induce GATA-3 expression, it was important to further elucidate the mechanism by which TCF-1 participated in GATA-3 induction. Consequently, we sought to determine if induction of Gata3-1b by TCF-1 in activated CD4 + T cells required the cofactor b-catenin. ICAT is a 9-kilodalton protein that has been shown to bind to b-catenin and inhibit its interaction with TCF-1 and impair TCF-1-and b-catenin-dependent transactivation of target genes 35 . Mice with enforced expression of ICAT from the proximal promoter of the gene encoding the kinase Lck (called 'ICAT mice' here) have been generated and analyzed 36 . CD4 + T cells from ICAT mice and control mice showed similar activation, proliferation and IL-2 production ( Supplementary Fig. 2 ). However, we found that activated ICAT CD4 + T cells also had lower expression of Gata3-1b than did control CD4 + T cells (Fig. 2b) . These data Figure 1 Initial GATA-3 expression in TCRactivated CD4 + T cells is from Gata3-1b transcripts. (a) Real-time RT-PCR analysis of the abundance of Gata3-1a and Gata3-1b transcripts (left) in control CD4 + T cells stimulated with plate-bound anti-CD3 plus anti-CD28, assessed at various times after activation; results are presented relative to the abundance of Actb (n ¼ 3 independent samples). Right, Gata3-1a PCR product relative to Gata3-1b PCR product (n ¼ 3 independent samples). Top, approximately 10 kb of Gata3, showing two regulatory regions upstream of noncoding exon 1a and exon 1b and the translation start site in exon 2. (b) Real-time RT-PCR analysis of Gata3-1b mRNA expression in enriched, naive control or STAT6-deficient (STAT6-KO) CD25 -CD4 + T cells stimulated for 3 d as described in a, presented relative to the abundance of mRNA in control cells, set as 100% (n ¼ 4 independent samples). (c) Real-time RT-PCR analysis of Gata3-1b mRNA expression in CD4 + T cells stimulated for 3 d as described in a, in the presence (Anti-IL-4) or absence (Medium) of an IL-4-specific antibody, presented relative to the abundance of mRNA in control cells, set as 100% (n ¼ 4 independent samples). Data are pooled from two independent experiments (error bars, s.e.m.).
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Exon show that deletion of TCF-1 or disruption of the TCF-1-b-catenin interaction by ICAT expression impairs GATA-3 expression. To determine if enforced expression of b-catenin enhanced Gata3-1b expression, we used CD4 + T cells from b-catenin-transgenic mice (b-CATTg mice) 37 . We found that b-CAT-Tg CD4 + T cells showed normal activation and proliferation compared with that of control CD4 + T cells but produced less IL-2 ( Supplementary Fig. 2 ). We also found that enforced expression of stabilized b-catenin 'preferentially' augmented Gata3-1b expression, without affecting Gata3-1a transcripts, in activated b-CAT-Tg CD4 + T cells (Fig. 2c) . Additionally, we found that retroviral expression of b-catenin rapidly induced expression of Gata3-1b transcripts in activated CD4 + T cells (Fig. 2d) . Finally, the abundance of total GATA-3 in the loss-of-function (TCF-1-deficient and ICAT) and gain-of-function (b-CAT-Tg) CD4 + T cells reflected the pattern noted for Gata3-1b ( Supplementary Fig. 3 ). Thus, these data document involvement of TCF-1, acting with its cofactor b-catenin, in the regulation of Gata3-1b expression in TCR-activated CD4 + T cells. Next we wanted to determine whether TCR stimulation of CD4 + T cells affected the expression and/or function, of TCF-1 or b-catenin. Resting (ex vivo) and TCR-activated CD4 + T cells express both TCF-1 and LEF (a TCF family protein that binds the same DNA sequence as TCF-1); however, the relative expression of TCF-1 was much higher than that of LEF when normalized to b-actin ( Supplementary Fig. 4a ). Ex vivo CD4 + T cells also expressed b-catenin, and this expression was slightly higher after TCR stimulation ( Supplementary Fig. 4b ). These data show that TCF-1 and b-catenin are expressed in resting and TCR-activated CD4 + T cells and that TCR signals lead to moderately greater b-catenin abundance, probably through protein stabilization. Expression of lacZ, which encodes b-galactosidase, was higher after TCR activation of CD4 + T cells from BAT-lacZ reporter mice (which express lacZ under control of a b-catenin-activated transgene; Supplementary Fig. 4c ). These data suggest that TCF-1 and b-catenin function to induce TCR-dependent gene expression. Finally, activated CD4 + T cells had higher expression of Bambi, a TCF-1 target gene 38 , than did resting CD4 + T cells ( Supplementary Fig. 4d ). Thus, TCR-dependent signals induce TCF-1 and b-catenin transactivation activity and the expression of target genes in CD4 + T cells.
The paucity of IL-4 at the start of an infection suggests that TCRdriven GATA-3 expression must be independent of IL-4 signaling during the initial phase of T H 2 differentiation. To test whether TCF-1-and b-catenin-induced Gata3-1b was independent of IL-4, we measured the abundance of Gata3-1b transcripts in vectortransduced and b-catenin-transduced CD4 + T cells treated with an IL-4-blocking antibody or without such antibody treatment. TCF-1 and b-catenin induced equivalent increases in Gata3-1b expression in the presence or absence of anti-IL-4 in the culture medium (Fig. 2e) .
To determine if TCF-1-and b-catenin-induced Gata3-1b expression required STAT6, we retrovirally transduced b-catenin into activated CD4 + T cells from STAT6-deficient and control mice and assayed the abundance of Gata3-1b transcripts relative to Actb (encoding b-actin). We found that there was greater relative abundance of Gata3-1b transcripts in b-catenin-transduced cells, which was not diminished in the absence of STAT6 (Fig. 2f) . Thus, the TCF-1-and b-catenininduced expression of GATA-3 from Gata3-1b transcripts was independent of IL-4, IL-4R and STAT6, which suggests involvement of these events in the initiation of T H 2 differentiation.
TCF and b-catenin bind Gata3-1b regulatory elements To determine if TCF-1 directly regulates GATA-3 expression from the regulatory sites upstream of Gata3 exon 1b, we did chromatinimmunoprecipitation assays with DNA from activated CD4 + T cells and anti-TCF-1 and anti-b-catenin. We found that TCF-1 bound to the TCF-1-binding sites in the regulatory region upstream of Gata3-1b in activated CD4 + T cells (Fig. 3a) . Likewise, b-catenin-specific antibodies immunoprecipitated the same DNA but not nonspecific DNA sequence that did not contain TCF-binding sites (Fig. 3a) . These data show that TCF-1 and b-catenin bind to the TCF-1-binding sites in the Gata3-1b regulatory region. Using purified preparations of recombinant LEF protein 39 , we also found by electrophoretic mobility-shift assay that LEF specifically bound to oligonucleotides corresponding to the Gata3-1b promoter sequence containing the TCF-binding site but not to sequence with a mutated TCF-binding site ( Supplementary Fig. 5 ). To further assess if the TCF-1-binding sites in the Gata3 regulatory region were functional, we generated a luciferase reporter plasmid containing Gata3-1b regulatory DNA sequences. We assayed reporter activity in the mouse T lymphoma cell line EL4, which has higher expression of b-catenin than that of resting CD4 + T cells (Fig. 3b) . We found constitutive luciferase activity with the wild-type TCF-1 reporter; however, expression was lower when the TCF-1 site was mutated (Fig. 3b) . These data show that TCF-1 and b-catenin bind to the identified binding sites upstream of Gata3 exon 1b and functionally activate transcription.
TCF-1-induced GATA-3 leads to IL-4 production To determine if impaired GATA-3 expression affects IL-4 production, we assayed TCR-activated CD4 + T cells from TCF-1-deficient, ICAT and b-CAT-Tg mice. We found that tenfold more activated control CD4 + T cells than activated TCF-1-deficient or ICAT-expressing CD4 + T cells produced IL-4 (Fig. 4a) . In contrast, fourfold more activated b-CAT-Tg CD4 + T cells than activated control CD4 + T cells produced IL-4 (Fig. 4a) . In addition, activated b-CAT-Tg CD4 + T cells produced more IL-4 per cell (Fig. 4a, arrows) . The changes in IL-4 production were not due to changes in IL-4R expression or the capacity of IL-4R to signal, as measured by IL-4-induced phosphorylation of STAT6, both of which were equivalent in TCF-1-deficient and control CD4 + T cells (Supplementary Fig. 6 ). Moreover, we found that the abundance of Il4 mRNA was also lower in TCR-activated TCF-1-deficient and ICAT T cells than in control CD4 + T cells (Fig. 4b) . In contrast, b-CAT-Tg CD4 + T cells had more Il4 mRNA (Fig. 4b) . These data show that TCF-1 and b-catenin regulate IL-4 production in activated CD4 + T cells in vitro.
To further substantiate the finding that TCF-1 and b-catenin act together to enhance IL-4 production, we used a mutant form of TCF-1 lacking the b-catenin-binding domain (mtTCF1) 39 (Fig. 4c) . We found that expression of mtTCF1 in activated CD4 + T cells resulted specifically in less Il4 mRNA but not less Il2 mRNA (Fig. 4d) . These data show that overexpression of a mutant TCF-1 that is unable to recruit b-catenin impairs IL-4 expression. Collectively these data show that TCF-1 and b-catenin act together to induce GATA-3 expression, which in turn leads to more IL-4 production by activated CD4 + T cells.
TCF-1 and b-catenin also regulate IL-4 production in vivo, as assessed after injection of staphylococcal enterotoxin B (SEB), which is an agonist for V b 8 + T cells. We found approximately 8.5-fold more IL-4 producing T cells in SEB-injected b-CAT-Tg mice than in SEB-injected control mice (Fig. 4e) . Conversely, the frequency of IL-4 producing T cells in SEB-injected ICAT mice was one-third that in SEB-injected control mice (Fig. 4e) . In these conditions, IL-4 production by cells of the innate immune system was very low and not different in control versus mutant mice ( Supplementary Fig. 7 ). These data show that TCF-1 and b-catenin act together to regulate IL-4 production in vivo and in vitro in antigen-activated CD4 + T cells.
TCF-1-induced IL-4 production is Notch independent
Notch-dependent transcription has been shown to regulate IL-4 production by inducing GATA-3 expression from the Gata3-1a promoter 15, 17 . To determine whether the induction of IL-4 production by TCF-1 and b-catenin depends on Notch signaling, we blocked Notch activity with a dominant negative form of the transcriptional coactivator Mastermind-like (dnMAML) and assayed IL-4 production in the presence and absence of b-catenin. We transduced control and b-CAT-Tg CD4 + T cells with retroviral constructs coexpressing dnMAML and green fluorescent protein (GFP) and assigned scores to the frequency of IL-4-producing cells among GFP + cells. As reported before 17 , expression of dnMAML resulted in a lower frequency of IL-4-producing cells among transduced control CD4 + T cells (Fig. 5) . Notably, enforced expression of b-catenin resulted in a fivefold higher frequency of IL-4-producing cells, which was not diminished by blocking Notch signaling with dnMAML (Fig. 5a) .
Moreover, Gata3-1b transcripts were not lower in abundance in either control or b-catenin-expressing CD4 + T cells transduced with dnMAML (Fig. 5b) . Thus, these data show that Gata3-1a and Gata3-1b are Notch-dependent and Notch-independent transcripts, respectively. We conclude that TCF-1 and b-catenin induce Gata3-1b expression and subsequent IL-4 production, which is independent of Notch signaling.
TCF-1 negatively regulates IFN-c production
Signals that induce GATA-3 expression and the T H 2 fate can also block IFN-g expression and the T H 1 fate 2, 3 . Therefore, we assessed whether TCF-1 and/or b-catenin also regulate IFN-g production and the T H 1 fate. We found that activated TCF-1-deficient CD4 + T cells produced more IFN-g than did wild-type control cells (Fig. 6a) , which suggested that TCF-1 negatively regulates IFN-g expression. On the basis of these data, we predicted that TCF-1 expression would be lower in T H 1-differentiated CD4 + T cells than in undifferentiated cells. Indeed, within 3 d of the differentiation of CD4 + T cells toward the T H 1 lineage, the abundance of TCF-1 mRNA decreased to one third that in control cells (Supplementary Fig. 8 ). Thus, TCF-1 is diminished after encounter with IL-12 and IFN-g, cytokines that promote the T H 1 fate. We also found that ICAT-expressing CD4 + T cells did not have more IFN-g production (data not shown). Thus, we conclude that the repressive effect of TCF-1 on IFN-g was not dependent on its interaction with b-catenin.
To further confirm that TCF-1 expression blocks IFN-g independently of b-catenin, we transduced CD4 + T cells with control retrovirus or retrovirus expressing mtTCF1, the mutant TCF-1 that cannot interact with b-catenin (Fig. 6b) and assayed IFN-g production. IFNg expression was lower in CD4 + T cells transduced with mtTCF1 (Fig. 6b,c) . Together these data demonstrate that in the absence of T H 1 cytokines, TCF-1 negatively regulates IFN-g and thereby blocks the T H 1 fate.
Deletion of TCF-1 impairs T H 2 responses in vivo
To determine if TCF-1-deficient mice had altered adaptive immune responses in vivo, we used a mouse model of allergic asthma. Nonimmunized control mice (injected with PBS) and TCF-1-deficient mice had similar cell counts in their bronchoalveolar lavage (BAL) fluid at baseline. As expected, after immunization and challenge with ovalbumin (OVA), control mice had significantly more total cells in the BAL fluid than did PBS-injected mice, as did immunized TCF-1-deficient mice (P ¼ 0.001; Fig. 7a, left) . In addition, analysis of differential cell counts showed that TCF-1-deficient mice and control mice had a similar number of lymphocytes in the BAL fluid (Fig. 7a,  right) . However, cytokine analysis showed that TCF-1-deficient mice had significantly less of the T H 2 cytokine IL-4 in the BAL fluid than did control mice (P ¼ 0.03; Fig. 7b ). Furthermore, lung histology showed that OVA-immunized and OVA-challenged control mice had more inflammatory cell infiltration in the perivascular and peribronchial areas, involving medium and large airways (Fig. 7c-e) . In contrast, immunized TCF-1-deficient mice had cell infiltration in the lung tissue ( Fig. 7c-e) , but it was mostly limited to the perivascular areas (Fig. 7d) with limited involvement of the peribronchial areas (Fig. 7e) , particularly the large airways (Fig. 7e ). These results demonstrate that after immunization, TCF-1-deficient mice attempt to mount an adaptive immune response to OVA allergen but with less production of the T H 2 cytokine IL-4 and visibly less inflammation around the airways in the lung.
DISCUSSION
We have demonstrated here that GATA-3 in CD4 + T cells was produced mainly from Gata3-1b transcripts early after TCR stimulation and in the absence of IL-4 and STAT6 signaling. We have shown that TCF-1 and b-catenin positively and directly regulated Gata3 expression by binding to TCF-1-binding sites in the Gata3 regulatory region upstream of exon 1b. Induction of GATA-3 by TCF-1 and b-catenin resulted in IL-4 production and initiation of the T H 2 fate. In addition, TCF-1 inhibited IFN-g production and T H 1 differentiation independently of its interaction with b-catenin. Therefore, we propose that TCF-1 facilitates the initiation of T H 2 differentiation by a dual mechanism: by inducing GATA-3 expression and by blocking IFN-g production.
Naive CD4 + T cells have low expression of GATA-3, which is induced in response to TCR and IL-4R signaling 9-12 from two alternative transcripts 13, 14 . In this report we have demonstrated that Gata3-1b transcripts were the main isoform expressed at early time points after TCR activation of CD4 + T cells independently of IL-4R signaling through STAT6. In our experiments, the abundance of Gata3-1a transcripts was much lower in TCR-stimulated CD4 + T cells and was induced at late times after stimulation. Whereas GATA-3 is produced mainly from Gata3-1b transcripts in activated CD4 + T cells, both transcripts were expressed with different kinetics, and further analysis is needed to delineate the importance of alternative use of these transcripts in activated CD4 + T cells. Furthermore, Notch signaling regulates Gata3-1a transcripts 15, 17 , whereas TCF-1 and b-catenin regulate Gata3-1b expression, during T H 2 differentiation. Although further studies are needed to demonstrate independent regulation of GATA-3 expression by Notch and TCF-1 in vivo, these data show that both transcripts contribute to GATA-3 expression during T H 2 differentiation. However, the timing and pattern of expression of Gata3-1b indicates it must initiate T H 2 differentiation.
To demonstrate the importance of TCF-1 in mounting a T H 2 response in vivo, we used an established mouse OVA model. We found that TCF-1-deficient mice were substantially impaired in mounting a T H 2 response to OVA allergen in vivo, which indicates an important function for TCF-1 in T H 2 responses in vivo. TCF-1 and b-catenin initiate the T H 2 differentiation of TCR-stimulated CD4 + T cells, as indicated by the following observations. First, TCF-1 and b-catenin induced GATA-3 from Gata3-1b transcripts 'downstream' of TCR signals within 16-24 h. Second, TCF-1 and b-catenin induced GATA-3 independently of IL-4 signaling through STAT6. Third, TCF-1-and b-catenininduced GATA-3 resulted in more IL-4 production. Thus, TCF-1-and b-catenin-induced GATA-3 expression meets the criteria for the initiation of T H 2 differentiation in conditions of low IL-4. Finally, TCF-1 negatively regulated IFN-g production and blocked T H 1 differentiation. Therefore, downregulation of TCF-1 is essential for differentiation to the T H 1 lineage. In agreement with that, we found that APC-derived IL-12 and IFN-g downregulated TCF-1 expression in CD4 + T cells. Thus, we propose that TCF-1 regulates T H 2 fate by two means: by inducing GATA-3 expression, which promotes IL-4 production, and by blocking IFN-g production.
We have shown here and others have shown before that activated T cells express components that mediate canonical Wnt signals 29, 32 . However, it remains unclear if TCR signals directly stabilize b-catenin or result in the induction of autocrine Wnt signaling, which then stabilizes b-catenin. Thus, the mechanism by which TCR signals lead to stabilization of b-catenin in activated CD4 + T cells requires further investigation. Pre-TCR signals stabilize b-catenin in thymocytes through phosphorylation of the kinase Erk 40 . By analogy with that, we speculate that Erk-dependent mechanisms may regulate inhibition of activity of the kinase GSK3b 41 and TCR-induced stabilization of b-catenin. We have also found that TCR signals lead to higher expression of various Wnt receptor components (data not shown), which may enhance the responsiveness of activated T cells to Wnt ligands. Thus, b-catenin is stabilized directly or indirectly 'downstream' of the TCR in activated CD4 + T cells. In addition, b-catenin may also be stabilized by microbial byproducts, such as prostaglandin E 2 , that promote T H 2 differentiation and have been shown to stabilize b-catenin in colon cancer cells [42] [43] [44] [45] [46] . Thus, stabilization of b-catenin by TCR signals as well as by T H 2-promoting agents acts together with TCF-1 to regulate initial GATA-3 expression and initiate T H 2 differentiation. Finally, two lines of evidence suggest that IFN-g production is negatively regulated by TCF-1. First, the higher frequency of activated TCF-1-deficient CD4 + T cells resulted in more production of IFN-g. Second, expression of a mutant TCF-1 that cannot bind b-catenin repressed IFN-g production in activated wild-type CD4 + T cells. However, at present there are no known, confirmed TCF-1-binding sites in the Ifng promoter. Thus, either the repression observed in our assays is indirect or TCF-1 acts directly through sequences distal from the promoter or through 'cooperation' with other factors that act on the proximal promoter. These and other possibilities will be an important focus of future studies in the field.
In conclusion, we have shown here that TCF-1 and b-catenin positively regulated Gata3-1b expression, which led to more IL-4 production in TCR-activated CD4 + T cells. These events occurred at early time points after CD4 + T cell activation, were cell intrinsic in nature and were independent of both IL-4 and Notch signaling. Together these data provide a model for the molecular basis of the initiation of the T H 2 fate. We suggest that TCF-1 and b-catenin bind a response element in the Gata3 regulatory region upstream of exon 1b to initiate transcription of Gata3-1b mRNA. Higher GATA-3 expression promotes IL-4 production and initiates T H 2 differentiation. Simultaneously, TCF-1 also inhibits IFN-g production and T H 1 differentiation independently of b-catenin. APC-derived IL-12 and IFN-g inhibit TCF-1 expression and block GATA-3 expression, thereby promoting T H 1 differentiation. Thus, TCF-1 initiates the T H 2 differentiation of activated CD4 + T cells by a dual mechanism of activation of GATA-3 and repression of IFN-g.
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